Financial boost for Leon Nanodrugs 

Munich-based startup Leon Nanodrugs has closed an oversubscribed funding round of undisclosed size. According to the company, both existing and new investors participated.

With this capital, Leon Nanodrugs intends to accelerate the market launch of its nanosystems. At the same time, the company plans to transition from the advanced development phase to full commercial use. Furthermore, it aims to expand its international sales to serve pharmaceutical and biotechnology companies worldwide. In doing so, the biotech startup seeks to strengthen its position as a technology provider for the industrial production of lipid nanoparticles.

Focus on the production of lipid nanoparticles

Leon Nanodrugs develops systems for the production of lipid nanoparticles, or LNPs for short. These particles serve as a transport shell for active substances. They deliver, for example, RNA molecules into cells and thus form the basis for RNA-based drugs, cancer vaccines, and cell and gene therapies.

Such therapies are often produced in small batches. At the same time, strict regulatory requirements apply. Production must be reproducible and meet defined quality standards. Furthermore, many development programs demand short lead times, even at later commercial scale.

Leon Nanodrugs addresses these requirements with a platform designed to enable standardized manufacturing from early development to commercial production. According to the company, the manufacturing process can be scaled up from laboratory to production scale without requiring fundamental modifications. With this, Leon Nanodrugs aims to advance the scalable production of lipid nanoparticles and strengthen manufacturing expertise within Munich's biotechnology sector.

Proprietary mixing technology as core

The platform's central element is the company's proprietary FR-JET technology. This is a special mixing process for manufacturing nanoparticles. The process is designed to allow for robust scaling while ensuring consistent product quality. According to the company, this reduces the operational risk when transitioning development projects to commercial manufacturing.

Christian Nafe, Chief Financial Officer of Leon Nanodrugs, says:

"The funding gives us the necessary momentum to expand our commercial presence, support our partners worldwide and advance the development of a production platform for the next generation of therapeutics."

There is also agreement from the investor side. Frank Mühlenbeck, managing partner at LBBW Venture Capital and chairman of the supervisory board of Leon Nanodrugs, explains:

"With market-ready systems, a differentiated technology base and growing customer demand, we believe Leon Nanodrugs is well positioned to establish itself as a leading company in scalable nanoparticle manufacturing."

For the Munich-based startup, the involvement of experienced investors underlines its ambition to scale up its technology to an industrial level and to position itself in international competition.